314 related articles for article (PubMed ID: 27105947)
1. Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies.
Ho GY; Woodward N; Coward JI
Crit Rev Oncol Hematol; 2016 Jun; 102():37-46. PubMed ID: 27105947
[TBL] [Abstract][Full Text] [Related]
2. Carboplatin versus cisplatin in solid tumors: an analysis of the literature.
Lokich J; Anderson N
Ann Oncol; 1998 Jan; 9(1):13-21. PubMed ID: 9541678
[TBL] [Abstract][Full Text] [Related]
3. Toxicity of platinum compounds.
Hartmann JT; Lipp HP
Expert Opin Pharmacother; 2003 Jun; 4(6):889-901. PubMed ID: 12783586
[TBL] [Abstract][Full Text] [Related]
4. A comparison of the platinum analogues in bladder cancer cell lines.
Powles T; Perry J; Shamash J; Liu W; Oliver T; Joel S
Urol Int; 2007; 79(1):67-72. PubMed ID: 17627172
[TBL] [Abstract][Full Text] [Related]
5. Nucleotide excision repair: why is it not used to predict response to platinum-based chemotherapy?
Bowden NA
Cancer Lett; 2014 May; 346(2):163-71. PubMed ID: 24462818
[TBL] [Abstract][Full Text] [Related]
6. [Cisplatin or carboplatin, that is the question].
Moncharmont C; Auberdiac P; Mélis A; Afqir S; Pacaut C; Chargari C; Merrouche Y; Magné N
Bull Cancer; 2011 Feb; 98(2):164-75. PubMed ID: 21382796
[TBL] [Abstract][Full Text] [Related]
7. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin.
Go RS; Adjei AA
J Clin Oncol; 1999 Jan; 17(1):409-22. PubMed ID: 10458260
[TBL] [Abstract][Full Text] [Related]
8. Platinum compounds in children with cancer: toxicity and clinical management.
Ruggiero A; Trombatore G; Triarico S; Arena R; Ferrara P; Scalzone M; Pierri F; Riccardi R
Anticancer Drugs; 2013 Nov; 24(10):1007-19. PubMed ID: 23962902
[TBL] [Abstract][Full Text] [Related]
9. Hypersensitivity reactions associated with platinum-containing antineoplastic agents for thoracic malignancies.
Tamiya M; Kuhara H; Hirashima T; Kondo Y; Santo M; Morishita N; Suzuki H; Sasada S; Okamoto N; Kobayashi M; Kawase I
Anticancer Res; 2011 Dec; 31(12):4525-8. PubMed ID: 22199326
[TBL] [Abstract][Full Text] [Related]
10. Platinum compounds in the treatment of advanced breast cancer.
Martín M
Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
[TBL] [Abstract][Full Text] [Related]
11. Comparison of platinum concentrations in human head and neck tumours following administration of carboplatin, iproplatin or cisplatin.
Hecquet B; Caty A; Fournier C; Lefebvre JL; Adenis L
Bull Cancer; 1987; 74(4):433-6. PubMed ID: 3311237
[TBL] [Abstract][Full Text] [Related]
12. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
Bonetti A; Apostoli P; Zaninelli M; Pavanel F; Colombatti M; Cetto GL; Franceschi T; Sperotto L; Leone R
Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137
[TBL] [Abstract][Full Text] [Related]
13. Comparative clinical pharmacology of cisplatin and carboplatin.
Murry DJ
Pharmacotherapy; 1997; 17(5 Pt 2):140S-145S. PubMed ID: 9322881
[TBL] [Abstract][Full Text] [Related]
14. Lung tumour growth delay and normal tissue toxicity induced by three cytotoxic platinum drugs.
van Rongen E; Kal HB; Kuijpers WC; van Berkel AH
Strahlenther Onkol; 1992 May; 168(5):300-7. PubMed ID: 1598667
[TBL] [Abstract][Full Text] [Related]
15. Clinical development of platinum complexes in cancer therapy: an historical perspective and an update.
Lebwohl D; Canetta R
Eur J Cancer; 1998 Sep; 34(10):1522-34. PubMed ID: 9893623
[TBL] [Abstract][Full Text] [Related]
16. Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review).
Boulikas T; Vougiouka M
Oncol Rep; 2004 Mar; 11(3):559-95. PubMed ID: 14767508
[TBL] [Abstract][Full Text] [Related]
17. New platinum agents. A comparison in ovarian cancer.
Kelland LR; McKeage MJ
Drugs Aging; 1994 Aug; 5(2):85-95. PubMed ID: 7981487
[TBL] [Abstract][Full Text] [Related]
18. Comparative adverse effect profiles of platinum drugs.
McKeage MJ
Drug Saf; 1995 Oct; 13(4):228-44. PubMed ID: 8573296
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity.
Awada A; Dumez H; Aftimos PG; Costermans J; Bartholomeus S; Forceville K; Berghmans T; Meeus MA; Cescutti J; Munzert G; Pilz K; Liu D; Schöffski P
Invest New Drugs; 2015 Jun; 33(3):611-20. PubMed ID: 25794535
[TBL] [Abstract][Full Text] [Related]
20. The future role of carboplatin.
Ruckdeschel JC
Semin Oncol; 1994 Oct; 21(5 Suppl 12):114-8. PubMed ID: 7992063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
